SB1043 would reduce Hawaii’s general excise tax rate on the sale of nonprescription drugs by one-half. The bill adds a new section to Chapter 237, Hawaii Revised Statutes, directing that the tax on gross proceeds or gross income from sales of over-the-counter medications be charged at 50 percent of the rate otherwise imposed under the general excise tax provision for retail sales. The bill defines “nonprescription drug” by reference to existing law in section 328-1.
The measure is framed as a targeted tax relief bill for households facing Hawaii’s high cost of living, especially low- and moderate-income families who pay the general excise tax on essential items. The findings section notes that a full exemption would reduce revenue too much, so the bill chooses a partial reduction rather than eliminating the tax entirely. The bill’s stated effective date is July 1, 3000, which appears to be a placeholder or drafting anomaly rather than a near-term implementation date.
Impact
If enacted, SB1043 would amend Chapter 237 to create a reduced general excise tax rate specifically for nonprescription drugs, lowering the tax burden on consumers purchasing over-the-counter medications and reducing tax collections from those sales. It would not eliminate the tax, but would require sellers and tax administrators to apply a special half-rate to qualifying products. The bill would affect retailers of nonprescription drugs, consumers, and state general fund revenues tied to general excise tax receipts.
Sentiment
The available voting history shows strong support in committee, with unanimous or near-unanimous passage in the Senate Labor and Technology, Health and Human Services, and Ways and Means committees, each with amendments. That pattern suggests broad agreement with the bill’s consumer-relief goal and its targeted approach to lowering costs for essential medicines. No committee transcript was provided, so there is no recorded floor or hearing debate to indicate organized opposition in the available materials.
Contention
The main policy tension identified in the bill itself is between providing tax relief on essential goods and preserving state revenue. The legislature explicitly acknowledges that fully exempting these products from the general excise tax would better address regressivity, but says the state’s fiscal needs would not support that approach. As a result, the bill settles on a partial reduction, which may leave some advocates wanting deeper relief while fiscal stakeholders may still scrutinize the revenue loss. The placeholder effective date also stands out as a drafting issue, though it is not a substantive policy dispute.
An Act to Require Health Insurance Coverage for Federally Approved Nonprescription Oral Hormonal Contraceptives and Nonprescription Emergency Contraceptives